tetano
Editor, Senior Moderator
Influenza Other Respir Viruses
. 2024 May;18(5):e13302.
doi: 10.1111/irv.13302. Comparative Effectiveness of Baloxavir Marboxil and Oseltamivir Treatment in Reducing Household Transmission of Influenza: A Post Hoc Analysis of the BLOCKSTONE Trial
Hideyuki Ikematsu[SUP] 1 [/SUP], Takamichi Baba[SUP] 2 [/SUP], Masaya M Saito[SUP] 3 [/SUP], Masahiro Kinoshita[SUP] 4 [/SUP], Shogo Miyazawa[SUP] 5 [/SUP], Ayano Hata[SUP] 5 [/SUP], Saki Nakano[SUP] 5 [/SUP], Yoshitake Kitanishi[SUP] 5 [/SUP], Frederick G Hayden[SUP] 6 [/SUP]
Affiliations
Background: The transmission of influenza virus in households, especially by children, is a major route of infection. Prior studies suggest that timely antiviral treatment of ill cases may reduce infection in household contacts. The aim of the study was to compare the effects of oseltamivir (OTV) and baloxavir marboxil (BXM) treatment of index cases on the secondary attack rate (SAR) of influenza within household.
Methods: A post hoc analysis was done in BLOCKSTONE trial-a placebo-controlled, double-blinded post-exposure prophylaxis of BXM. Data were derived from the laboratory-confirmed index cases' household contacts who received placebo in the trial and also from household members who did not participate in the trial but completed illness questionnaires. To assess the SAR of household members, multivariate analyses adjusted for factors including age, vaccination status, and household size were performed and compared between contacts of index cases treated with BXM or OTV.
Results: In total, 185 index cases (116 treated with BXM and 69 treated with OTV) and 410 household contacts (201 from trial, 209 by questionnaire) were included. The Poisson regression modeling showed that the SAR in household contacts of index cases treated with BXM and OTV was 10.8% and 18.5%, respectively; the adjusted relative reduction in SAR was 41.8% (95% confidence interval: 1.0%-65.7%, p = 0.0456) greater with BXM than OTV. Similar reductions were found in contacts from the trial and those included by questionnaire.
Conclusion: BXM treatment of index cases appeared to result in a greater reduction in secondary household transmission than OTV treatment.
Keywords: Japan; baloxavir marboxil; household transmission; influenza treatment; oseltamivir.
. 2024 May;18(5):e13302.
doi: 10.1111/irv.13302. Comparative Effectiveness of Baloxavir Marboxil and Oseltamivir Treatment in Reducing Household Transmission of Influenza: A Post Hoc Analysis of the BLOCKSTONE Trial
Hideyuki Ikematsu[SUP] 1 [/SUP], Takamichi Baba[SUP] 2 [/SUP], Masaya M Saito[SUP] 3 [/SUP], Masahiro Kinoshita[SUP] 4 [/SUP], Shogo Miyazawa[SUP] 5 [/SUP], Ayano Hata[SUP] 5 [/SUP], Saki Nakano[SUP] 5 [/SUP], Yoshitake Kitanishi[SUP] 5 [/SUP], Frederick G Hayden[SUP] 6 [/SUP]
Affiliations
- PMID: 38706384
- PMCID: PMC11070769
- DOI: 10.1111/irv.13302
Background: The transmission of influenza virus in households, especially by children, is a major route of infection. Prior studies suggest that timely antiviral treatment of ill cases may reduce infection in household contacts. The aim of the study was to compare the effects of oseltamivir (OTV) and baloxavir marboxil (BXM) treatment of index cases on the secondary attack rate (SAR) of influenza within household.
Methods: A post hoc analysis was done in BLOCKSTONE trial-a placebo-controlled, double-blinded post-exposure prophylaxis of BXM. Data were derived from the laboratory-confirmed index cases' household contacts who received placebo in the trial and also from household members who did not participate in the trial but completed illness questionnaires. To assess the SAR of household members, multivariate analyses adjusted for factors including age, vaccination status, and household size were performed and compared between contacts of index cases treated with BXM or OTV.
Results: In total, 185 index cases (116 treated with BXM and 69 treated with OTV) and 410 household contacts (201 from trial, 209 by questionnaire) were included. The Poisson regression modeling showed that the SAR in household contacts of index cases treated with BXM and OTV was 10.8% and 18.5%, respectively; the adjusted relative reduction in SAR was 41.8% (95% confidence interval: 1.0%-65.7%, p = 0.0456) greater with BXM than OTV. Similar reductions were found in contacts from the trial and those included by questionnaire.
Conclusion: BXM treatment of index cases appeared to result in a greater reduction in secondary household transmission than OTV treatment.
Keywords: Japan; baloxavir marboxil; household transmission; influenza treatment; oseltamivir.